Tenecteplase Now Reimbursed in Belgium

by | 3 Apr 2025 | News, professionals

Starting May 2, Tenecteplase will be reimbursed in Belgium, with a price of €852.20 per vial (25mg), which is in line with the price of Alteplase (thrombolytic agent currently used in acute stroke care).

What is Tenecteplase?

Tenecteplase is a genetically modified variant of alteplase, designed to provide several key advantages in the treatment of acute ischemic stroke. It has a higher specificity for fibrin, which means it more effectively targets the clot.

In addition, Tenecteplase has a longer half-life than alteplase, enabling it to be administered as a single bolus dose. The simplified dosing regimen (dose adaptation to weight in steps of 10kg instead of 1kg) makes it easier to administer. This simplifies the treatment process, eliminating the need for the continuous infusion required with alteplase and reducing the chances of dosing errors.

Research shows that Tenecteplase is at least as effective as alteplase in achieving successful reperfusion and improving patient outcomes. Moreover, Tenecteplase has been shown to be as safe as alteplase, offering a valuable option for stroke care.

If you are interested, read here the recommendation on the use of tenecteplase by ESO published in 2023.

Neurosonology Conference 2025 on September 18–19, in Maastricht.

by | 19 Mar 2025 | congress, Event, News, professionals

Dear members and sympathizers of the BSC,

Join us for the Neurosonology Conference 2025 on September 18–19, in Maastricht, the Netherlands. This leading conference brings together experts in cerebrovascular and neuromuscular ultrasound and neuroimaging, featuring 25+ lectures, 8 interactive workshops, and the latest research in the field. Engage with leading professionals, explore cutting-edge advancements, and enhance your expertise. Don’t miss this key event for neurologists, neuro-intensivists, radiologists, sonographers and clinical researchers! Program and registration via https://neurosonology2025.com/.

The conference is endorsed by the Dutch Society for Clinical Neurophysiology, the Belgian Stroke Council, the Luxembourg Neurological Society and the World Organisation of Neurosonology (WON, previously ESNCH)

BSC members have 10% discount on the registration fee. They can claim this discount by using the promo code “member” when registering.

 

Sylvie De Raedt

on behalf of the BSC and the organising committee of the Neurology Conference 2025

BSC statement regarding the use of TNK for treatment of acute ischemic stroke

by | 18 Sep 2024 | News, professionals, Research

The Belgian Stroke Council is currently awaiting a decision by FAGG and RIZIV/INAMI regarding marketing and reimbursement of tenecteplase (TNK) for treatment of acute ischemic stroke in Belgium.

Based on the current evidence obtained from randomized, controlled trials comparing TNK with alteplase (tPA), the European Stroke Organisation (ESO) has stated that TNK (dosed at 0.25mg/kg) may be used as an alternative for tPA in eligible patients with acute ischemic stroke. The effectiveness and safety of TNK is comparable to tPA. Acute stroke patients with an occlusion of a large intracranial blood vessel may particularly benefit from TNK.

For more information, we refer to the BSC opinion statement and the ESO guideline on the use of TNK, attached to this post.

BSC opinion statement in dutch

BSC opinion statement in french

ESO guideline on TNK use

Remboursement Xarelto 2,5 mg

by | 13 Feb 2024 | News, professionals

We are delighted to announce that neurologists also have been recognised for the reimbursement of Xarelto 2.5mg in coronary artery disease (CAD) and peripheral artery disease PAD), since February 1, 2024.
Furthermore, the duration of acceptance has been changed, since the 3-year limit has been withdrawn.

 

Please find attached Bayer’s information letter: BE.XAR.VAE_Remboursement CADPAD_FR